ArticleJournal of cell communication and signaling2026
Pluripotent stem cell-derived extracellular vesicles: Cell type-dependent effect on tumorigenicity in cancer cell lines.
Article in Journal of cell communication and signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) derived from pluripotent stem cells have been reported to reprogram cancer cells to a more benign phenotype, due to its provision of an embryonic microenvironment. Here, we show that the effect of the EVs on the tumorigenicity of the cancer cell lines is cell type-dependent. First, we characterized the complement of transcription factors contained in EVs derived from human embryonic and induced pluripotent stem cell lines and subsequently treated MCF7, A431, MDA-MB-231, and DLD-1 cancer cell lines with the EVs derived from these pluripotent stem cell lines. For EV-treated MDA-MB-231 and DLD-1 cells, we found a decrease in the protein expression of CD44 and C24, which are accepted markers for cancer cell populations enriched with tumor-initiating cells, a result that corresponds to the previous reports. However, for EV-treated MCF7 and A431 cells, there was an increase in the protein expression of CD44 and C24 instead, with a corresponding increase in clonogenicity and resistance to a panel of anticancer drugs, when compared to non-exosome-treated cells. When subcutaneously implanted in nude mice, EV-treated MCF7 cells gave rise to tumors of larger size than untreated cells. The cell type-dependence of the effect of hPSC-derived EV treatment was postulated to be due to occurrence of an EMT for cells located at different locations along the epithelial-mesenchymal spectrum, leading to either an increase or decrease in tumorigenicity. Therefore, exposure to EVs does not always reduce the tumorigenicity of cancer cells but is cell type-dependent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.